RNA PEER ANALYSIS

Atrium Therapeutics, Inc. Common Stock — metric-by-metric comparison with peers and the industry median

RNAAtrium Therapeutics, Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

RNAIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	RNA	MSB	RTALB	TLX	Ind. Median
P/E	—	—	4.89	—	17.91
P/B	1.00	—	0.61●	6.37	3.51
EV/EBITDA	—	—	74.61●	120.14	14.82
P/S	6.34	31.61	6.67	3.24●	10.89

Financial Health
Metric	RNA	MSB	RTALB	TLX	Ind. Median
Current Ratio	13.04●	—	1.21	1.43	5.90
Debt/Equity	1.1%●	—	1.2%	112.3%	10.9%
NetDebt/EBITDA	0.65●	—	0.90	13.13	1.15

Profitability
Metric	RNA	MSB	RTALB	TLX	Ind. Median
Net Margin	-1,076.9%	-115.3%	136.3%●	-0.9%	-125.7%
ROE	-50.7%	-11.3%	15.1%●	-1.8%	-47.5%
ROA	-45.3%	-8.6%	13.1%●	-0.7%	-35.8%
EBITDA Margin	-1,108.5%	-76.6%	9.0%●	3.0%	-105.8%

Growth + Dividend
Metric	RNA	MSB	RTALB	TLX	Ind. Median
Rev. Growth	312.4%	410.4%●	24.0%	56.3%	5.1%
NI Growth	—	—	134.0%	—	12.1%
Div. Yield	—	0.0%●	0.0%●	—	0.2%
Payout	—	0.0%	0.0%	—	0.0%

Valuation
Metric	RNA	KPTI	IMRX	NKTX	ALEC	VYGR	Ind. Median
P/E	—	—	—	—	—	—	17.91
P/B	1.00	-0.89●	0.00	0.84	21.94	1.29	3.51
EV/EBITDA	—	—	—	—	—	—	14.82
P/S	6.34	1.57●	—	—	12.37	6.16	10.89

Financial Health
Metric	RNA	KPTI	IMRX	NKTX	ALEC	VYGR	Ind. Median
Current Ratio	13.04	1.08	32.45●	12.96	5.25	8.42	5.90
Debt/Equity	1.1%	-86.9%●	1.8%	26.2%	332.8%	19.9%	10.9%
NetDebt/EBITDA	0.65	-0.95	-60.72●	1.71	1.48	0.95	1.15

Profitability
Metric	RNA	KPTI	IMRX	NKTX	ALEC	VYGR	Ind. Median
Net Margin	-1,076.9%	-129.0%●	—	—	-680.8%	-319.6%	-125.7%
ROE	-50.7%	—	-0.1%●	-30.1%	-238.9%	-52.3%	-47.5%
ROA	-45.3%	-150.5%	-0.1%●	-23.7%	-38.7%	-40.7%	-35.8%
EBITDA Margin	-1,108.5%	-97.9%●	—	—	-632.1%	-308.4%	-105.8%

Growth + Dividend
Metric	RNA	KPTI	IMRX	NKTX	ALEC	VYGR	Ind. Median
Rev. Growth	312.4%●	6.3%	-100.0%	-100.0%	-79.2%	-45.5%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RNA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.